GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:GLYC
- CUSIP: N/A
- Web: www.glycomimetics.com
Capitalization:- Market Cap: $342.94 million
- Outstanding Shares: 32,723,000
Average Prices:- 50 Day Moving Avg: $11.25
- 200 Day Moving Avg: $8.32
- 52 Week Range: $3.82 - $16.94
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.05
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $18,500.00
- Price / Sales: 18,537.14
- Book Value: $3.53 per share
- Price / Book: 2.97
Profitability:- EBIDTA: ($32,240,000.00)
- Return on Equity: -57.51%
- Return on Assets: -51.78%
Debt:- Current Ratio: 21.99%
- Quick Ratio: 21.99%
Misc:- Average Volume: 2.69 million shs.
- Beta: 3.23
- Short Ratio: 10.99
Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.07. View GlycoMimetics' Earnings History.
Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?
5 brokerages have issued 12-month price targets for GlycoMimetics' shares. Their predictions range from $9.00 to $21.00. On average, they expect GlycoMimetics' share price to reach $14.75 in the next year. View Analyst Ratings for GlycoMimetics.
What are analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
- 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (8/7/2017)
- 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Cytokinetics, Incorporated (CYTK), Aclaris Therapeutics (ACRS), Insys Therapeutics (INSY), Synergy Pharmaceuticals (SGYP), Achillion Pharmaceuticals (ACHN), La Jolla Pharmaceutical Company (LJPC), REGENXBIO (RGNX), Alder BioPharmaceuticals (ALDR), Versartis (VSAR), MacroGenics (MGNX), Coherus BioSciences (CHRS), Otonomy (OTIC), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB), Audentes Therapeutics (BOLD), Aurinia Pharmaceuticals (AUPH), Ignyta (RXDX) and CytomX Therapeutics (CTMX).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- M. James E. Barrett Ph.D., Chairman of the Board
- Rachel K. King, President, Chief Executive Officer, Founder, Director
- Brian Hahn, Chief Financial Officer
- John Magnani Ph.D., Chief Scientific Officer, Vice President - Research, Director
- Helen M. Thackray M.D., Vice President - Clinical Development, Chief Medical Officer
- Patricia S. Andrews, Director
- Mark Alan Goldberg M.D., Director
- Daniel M. Junius, Director
- Scott Koenig M.D., Ph.D., Director
- Timothy R. Pearson, Director
Who owns GlycoMimetics stock?
GlycoMimetics' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (34.84%), Franklin Resources Inc. (7.54%), Jennison Associates LLC (6.47%), FMR LLC (6.10%), Vanguard Group Inc. (3.43%) and Redmile Group LLC (1.83%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.
Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?
GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., State Street Corp, Northern Trust Corp and Nationwide Fund Advisors. View Insider Buying and Selling for GlycoMimetics.
Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?
GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Franklin Resources Inc., Redmile Group LLC, Janus Henderson Group PLC, Vanguard Group Inc., EAM Investors LLC and Broadfin Capital LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.
How do I buy GlycoMimetics stock?
Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GlycoMimetics stock can currently be purchased for approximately $10.48.
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $14.75 (40.74% upside) |
Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/7/2017 | SunTrust Banks, Inc. | Set Price Target | Buy | $21.00 | Low |  |
| 8/4/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $13.00 -> $17.00 | Low | |
| 6/6/2017 | Jefferies Group LLC | Lower Price Target | Buy | $16.00 -> $9.00 | High | |
| 5/28/2017 | Cowen and Company | Reiterated Rating | Outperform | | Low | |
| 5/19/2017 | Canaccord Genuity | Reiterated Rating | Buy | $12.00 | High | |
(Data available from 8/18/2015 forward)
Earnings History for GlycoMimetics (NASDAQ:GLYC)Earnings History by Quarter for GlycoMimetics (NASDAQ GLYC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.37) | ($0.30) | | | View | N/A | |
| 5/8/2017 | Q1 2017 | ($0.37) | ($0.34) | | | View | N/A | |
| 3/1/2017 | Q4 2016 | ($0.35) | ($0.36) | $4.50 million | | View | N/A | |
| 11/4/2016 | Q216 | ($0.44) | ($0.34) | | $0.02 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.47) | ($0.40) | | | View | N/A | |
| 2/29/2016 | Q4 | ($0.38) | ($0.47) | | $35.00 million | View | N/A | |
| 11/12/2015 | Q3 | ($0.40) | ($0.38) | $2.10 million | | View | N/A | |
| 8/6/2015 | Q2 2015 | ($0.40) | $0.51 | | $20.04 million | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.22) | ($0.39) | | | View | N/A | |
| 10/31/2014 | Q314 | $0.21 | ($0.35) | $10.00 million | | View | N/A | |
| 7/31/2014 | Q2 2014 | $0.24 | $0.39 | $9.08 million | $15.03 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.28) | ($0.30) | | | View | N/A | |
| 3/31/2014 | | ($2.17) | ($2.80) | $9.65 million | $0.08 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)2017 EPS Consensus Estimate: ($1.42)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.38) | ($0.37) | ($0.38) |
| Q2 2017 | 2 | ($0.40) | ($0.30) | ($0.35) |
| Q3 2017 | 2 | ($0.43) | ($0.25) | ($0.34) |
| Q4 2017 | 2 | ($0.44) | ($0.26) | ($0.35) |
(Data provided by Zacks Investment Research)
Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ:GLYC)Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 63.69%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | Helen M Thackray | SVP | Sell | 2,000 | $15.57 | $31,140.00 | |
| 5/19/2017 | Helen M Thackray | SVP | Sell | 2,000 | $12.14 | $24,280.00 | |
| 12/20/2016 | Daniel M. Junius | Director | Buy | 5,000 | $6.01 | $30,050.00 | |
| 10/3/2016 | Helen M Thackray | VP | Sell | 4,000 | $7.00 | $28,000.00 | |
| 7/20/2016 | Helen M Thackray | VP | Sell | 2,000 | $8.00 | $16,000.00 | |
| 7/6/2016 | Helen M Thackray | CMO | Sell | 22,000 | $7.00 | $154,000.00 | |
| 3/4/2016 | Mark Alan Goldberg | Director | Buy | 10,397 | $4.77 | $49,593.69 | |
| 12/22/2014 | Michael A Henos | Director | Sell | 21,257 | $8.52 | $181,109.64 | |
| 12/17/2014 | Michael A Henos | Director | Sell | 6,725 | $8.97 | $60,323.25 | |
| 12/15/2014 | Michael A Henos | Director | Sell | 1,604 | $8.98 | $14,403.92 | |
| 6/13/2014 | Michael A Henos | Director | Buy | 11,000 | $6.39 | $70,290.00 | |
| 1/15/2014 | Enterprise Associates 13 L New | Major Shareholder | Buy | 512,500 | $8.00 | $4,100,000.00 | |
| 1/15/2014 | M James Barrett | Director | Buy | 1,000,000 | $8.00 | $8,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GlycoMimetics (NASDAQ:GLYC)
Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
| Source: |
|
| Date | Headline |
|---|
 | Q3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust Banks
www.americanbankingnews.com - August 9 at 8:08 AM |
 | GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017
finance.yahoo.com - August 8 at 6:48 PM |
| GlycoMimetics, Inc. (GLYC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 8 at 12:34 AM |
| GlycoMimetics, Inc. (GLYC) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - August 5 at 9:56 PM |
| GlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 8:56 PM |
| Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS
www.americanbankingnews.com - August 5 at 12:44 PM |
| Stifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC)
www.americanbankingnews.com - August 5 at 11:34 AM |
| GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017
finance.yahoo.com - August 1 at 7:41 PM |
| GlycoMimetics, Inc. (GLYC) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 20 at 10:46 PM |
| GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017
finance.yahoo.com - July 19 at 7:45 PM |
| GlycoMimetics, Inc. (NASDAQ:GLYC) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 11:32 PM |
| Zacks: Analysts Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.38 EPS
www.americanbankingnews.com - July 14 at 11:14 AM |
| GlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:50 PM |
 | FDA Issues an Approval Not Seen in Almost 20 Years
247wallst.com - July 8 at 11:07 AM |
 | BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271
www.reuters.com - July 6 at 8:59 PM |
| GlycoMimetics to Receive European Patent for GMI-1271
finance.yahoo.com - July 6 at 8:59 PM |
| Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?
finance.yahoo.com - June 30 at 3:22 PM |
| Zacks: Brokerages Expect GlycoMimetics, Inc. (GLYC) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - June 20 at 8:18 AM |
| GlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 16 at 6:32 PM |
| GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
finance.yahoo.com - June 12 at 6:16 PM |
| Short Interest in GlycoMimetics Inc (GLYC) Rises By 248.2%
www.americanbankingnews.com - June 11 at 7:24 AM |
| FY2017 EPS Estimates for GlycoMimetics Inc (GLYC) Boosted by Analyst
www.americanbankingnews.com - June 8 at 8:26 AM |
| Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics
finance.yahoo.com - June 7 at 10:52 AM |
| GlycoMimetics' (GLYC) Buy Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - June 6 at 11:38 PM |
| GlycoMimetics Inc (GLYC) Price Target Raised to $16.00
www.americanbankingnews.com - June 6 at 9:18 AM |
| BRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
www.reuters.com - June 5 at 5:35 PM |
| GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 5:35 PM |
| GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting
finance.yahoo.com - June 5 at 10:53 AM |
| GlycoMimetics Inc (GLYC) Upgraded at ValuEngine
www.americanbankingnews.com - June 4 at 2:32 PM |
 | ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD
www.rttnews.com - May 31 at 9:02 AM |
| GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
finance.yahoo.com - May 31 at 9:02 AM |
| Helen M. Thackray Sells 2,000 Shares of GlycoMimetics Inc (GLYC) Stock
www.americanbankingnews.com - May 30 at 8:31 PM |
| GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 30 at 5:22 PM |
| Cowen and Company Reaffirms Outperform Rating for GlycoMimetics Inc (GLYC)
www.americanbankingnews.com - May 28 at 9:34 AM |
 | GlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AML
www.streetinsider.com - May 25 at 7:52 PM |
| BRIEF-Glycomimetics Inc terminates sales agreement with Cowen and Company
www.reuters.com - May 25 at 7:52 PM |
| GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
finance.yahoo.com - May 25 at 7:52 PM |
| Here's Why GlycoMimetics Rose as Much as 21% Today
finance.yahoo.com - May 25 at 7:52 PM |
| GlycoMimetics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 24 at 11:56 AM |
| GlycoMimetics (GLYC) Plans 6M Share Common Stock Offering
www.streetinsider.com - May 23 at 5:07 PM |
| GlycoMimetics Inc. (GLYC) Is Down Following Offering Announcement
www.rttnews.com - May 23 at 5:07 PM |
| Shark Bites: There Wasn't Even a Dip to Buy
finance.yahoo.com - May 23 at 11:44 AM |
| GlycoMimetics Inc (GLYC) SVP Helen M. Thackray Sells 2,000 Shares
www.americanbankingnews.com - May 22 at 10:28 PM |
| GlycoMimetics Inc (GLYC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 6:20 PM |
| GlycoMimetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 22 at 5:02 PM |
 | Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
www.nasdaq.com - May 19 at 10:16 PM |
| GlycoMimetics Inc (GLYC) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 19 at 9:36 PM |
| Why GlycoMimetics Is Ripping 19% Higher Today
finance.yahoo.com - May 19 at 5:15 PM |
| ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017
finance.yahoo.com - May 19 at 5:15 PM |
| GlycoMimetics Inc. (GLYC) Soared To A New High On FDA Breakthrough Designation
www.rttnews.com - May 19 at 8:36 AM |
GlycoMimetics (GLYC) Chart for Friday, August, 18, 2017
